The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe obstructive sleep apnea for people with obesity.

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but potentially serious sleep-related breathing disorder, making it the first medication for certain patients with the condition.

Eli Lilly said the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first and only prescription medicine for those suffering from this condition.

Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep apnea.

The drug is known as Zepbound and is the same as the chemical drug Tirzepatide. "See To Believe uncovers the forgotten, mind-blowing facts that will leave you questioning everything. Follow wild stories of mysterious creatures,